摘要 |
<p>There are provided derivatives having PPAR agonist activity. The derivatives include compounds and/or their pharmaceutically acceptable salts; the compounds having the formula (I) wherein A has the structure (II) or (III); X is chosen from -CH<SUB>2</SUB>-, -O-, -NH-, and -S-; Y is chosen from -O-, -NH-, and -S-; Z, which may be located in any position of substitution, is hydrogen or halogen; R<SUP>1 </SUP>and R<SUP>2</SUP>, which may be the same or different, are independently chosen from hydrogen and C<SUB>1</SUB>-C<SUB>8 </SUB>alkyl, or R<SUP>1 </SUP>and R<SUP>2 </SUP>together form a carbocyclic ring having from 4 to 6 carbon atoms; R<SUP>3 </SUP>is chosen from hydrogen and C<SUB>1</SUB>-C<SUB>8 </SUB>alkyl; R<SUP>4</SUP>, R<SUP>5</SUP>, and R<SUP>6</SUP>, which may be the same or different, are independently chosen from hydrogen and C<SUB>1</SUB>-C<SUB>8 </SUB>alkyl; and n is 1 to 6. Various embodiments and variants are provided. In accordance with other aspects, the invention also provides methods of producing a PPARalpha agonist activity in a mammal, the methods including administering to the mammal an effective amount of certain derivative(s) of the first aspect of the invention, a method of producing a PPARalpha agonist activity and a PPARalpha agonist activity in a mammal, the method including administering to the mammal an effective amount of certain derivative(s); and a pharmaceutical composition that includes the derivative(s) of the first aspect of the invention and one or more pharmaceutically-acceptable excipients. Various embodiments and variants are provided.</p> |